

**ANCOVA of Change from Baseline in  
Fasting Glucose (mmol/L) at Week 24 (LOCF)  
Efficacy Analysis Population**

| <b>Treatment Group</b>           | <b>Baseline</b>                                   |                  | <b>Week 24 (LOCF)</b> |                  | <b>Change from Baseline</b> |                            | <b>LS Mean (95% CI)<sup>a</sup></b> |
|----------------------------------|---|------------------|-----------------------|------------------|-----------------------------|----------------------------|-------------------------------------|
|                                  | <b>N</b>  | <b>Mean (SD)</b> | <b>N</b>              | <b>Mean (SD)</b> | <b>N</b>                    | <b>Mean (SD)</b>           |                                     |
| Placebo                          | 79  | 5.7 (2.23)       | 79                    | 5.6 (1.65)       | 79                          | -0.0 (2.32)                | 0.07 (-0.26, 0.41)                  |
| Xanomeline Low Dose              | 79  | 5.4 (0.95)       | 79                    | 5.4 (1.06)       | 79                          | -0.1 (1.02)                | -0.11 (-0.44, 0.23)                 |
| Xanomeline High Dose             | 74  | 5.4 (1.37)       | 74                    | 5.8 (2.21)       | 74                          | 0.4 (1.65)                 | 0.39 (0.04, 0.74)                   |
| <b>Pairwise Comparison</b>       | <b>Difference in LS Mean (95% CI)<sup>a</sup></b> |                  |                       |                  |                             | <b>p-Value<sup>b</sup></b> |                                     |
| Xanomeline Low Dose vs. Placebo  | -0.18 (-0.65, 0.30)                               |                  |                       |                  |                             |                            | 0.4670                              |
| Xanomeline High Dose vs. Placebo | 0.32 (-0.17, 0.80)                                |                  |                       |                  |                             |                            | 0.2004                              |

<sup>a</sup>LS means and differences in LS means are based on an ANCOVA model with treatment and baseline glucose as covariates.

<sup>b</sup>p-values are from the ANCOVA model testing treatment effects

LOCF (Last Observation Carried Forward) approach is used for missing Week 24 values.

ANCOVA = Analysis of Covariance; CI = Confidence Interval; LS = Least Squares; SD = Standard Deviation

Source: ADLBC Analysis Dataset

Analysis conducted: 12NOV2025

Statistical software: Python (statsmodels)